Pulse Biosciences (PLSE)
(Delayed Data from NSDQ)
$17.87 USD
-0.86 (-4.59%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $17.89 +0.02 (0.11%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Pulse Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 44 | 61 | 29 | 20 | 25 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 6 | 0 | 0 |
Other Current Assets | 1 | 1 | 2 | 2 | 1 |
Total Current Assets | 45 | 62 | 37 | 22 | 26 |
Net Property & Equipment | 2 | 2 | 2 | 2 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 5 | 5 | 6 | 7 | 7 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 59 | 78 | 54 | 41 | 42 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 3 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 1 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 3 | 4 | 5 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 7 | 6 | 9 | 8 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 65 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 15 | 80 | 19 | 18 | 11 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 381 | 292 | 272 | 195 | 153 |
Retained Earnings | -337 | -295 | -236 | -173 | -123 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 44 | -2 | 36 | 23 | 31 |
Total Liabilities & Shareholder's Equity | 59 | 78 | 54 | 41 | 42 |
Total Common Equity | 44 | -2 | 36 | 23 | 31 |
Shares Outstanding | 55.00 | 37.20 | 29.60 | 25.30 | 20.70 |
Book Value Per Share | 0.81 | -0.06 | 1.21 | 0.90 | 1.49 |
Fiscal Year End for Pulse Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 26 | 35 | 44 | 50 | 59 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 1 | 1 |
Total Current Assets | 27 | 36 | 45 | 52 | 60 |
Net Property & Equipment | 1 | 1 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 4 | 5 | 5 | 5 | 5 |
Deposits & Other Assets | 1 | 0 | 0 | 0 | 0 |
Total Assets | 40 | 49 | 59 | 66 | 75 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 2 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 2 | 4 | 3 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 6 | 5 | 7 | 5 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 13 | 13 | 15 | 14 | 14 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 385 | 383 | 381 | 377 | 375 |
Retained Earnings | -358 | -347 | -337 | -325 | -314 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 27 | 36 | 44 | 52 | 61 |
Total Liabilities & Shareholder's Equity | 40 | 49 | 59 | 66 | 75 |
Total Common Equity | 27 | 36 | 44 | 52 | 61 |
Shares Outstanding | 61.20 | 61.20 | 55.00 | 54.90 | 54.70 |
Book Value Per Share | 0.44 | 0.59 | 0.81 | 0.95 | 1.11 |